RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

OT: BVF
I was referring to the RD project only--and why that would separate out from SA from Biovail's commercial viewpoint. It has nothing to do with the rest of their portfolio. They're vertically integrated, so everything has a destiny in their marketing schema. AZ004, CX717 will be sold to hospitals. Wellbutrin and pimavanserin, to psychiatrists--maybe neurology if the PD psychosis indication pans out.. Now if their GDNF program ever gets anywhere, that would open up neurology, but that still wouldnt tap sleep labs per se. Fibiger is, as I said, constrained by the exclusion of anything that requires a huge PCP sales force. That leaves plenty of room for flexibility.

NeuroInvestment